InMed Pharmaceuticals CEO Eric Adams' 2024 pay rises 13% to $415K
InMed Pharmaceuticals reports 2024 executive compensation
By ExecPay News
Published: October 28, 2024
InMed Pharmaceuticals reported fiscal year 2024 executive compensation information on October 28, 2024.
In 2024, six executives at InMed Pharmaceuticals received on average a compensation package of $255K, a 5% increase compared to previous year.
Eric A. Adams, Chief Executive Officer, received $415K in total, which increased by 13% compared to 2023. 71% of Adams' compensation, or $294K, was in salary. Adams also received $74K in bonus and $48K in option awards.
Michael Woudenberg, Chief Operating Officer, received a compensation package of $349K, which increased by 17% compared to previous year. 78% of the compensation package, or $272K, was in salary.
Eric Hsu, Senior Vice President, Preclinical Research & Development, earned $323K in 2024, a 24% increase compared to previous year.
Alexandra Mancini, Senior Vice President, Clinical & Regulatory Affairs, received $314K in 2024, which increases by 10% compared to 2023.
Netta Jagpal, Chief Financial Officer, earned $121K in 2024.
Jonathan Tegge, Chief Financial Officer, received $11K in 2024, which increases by 400% compared to 2023.
InMed Pharmaceuticals' fiscal year ends on June 30.
Related executives
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
Netta Jagpal
InMed Pharmaceuticals
Chief Financial Officer
Jonathan Tegge
InMed Pharmaceuticals
Chief Financial Officer
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
Eric Hsu
InMed Pharmaceuticals